Preparation method of deuterated drug impurity norfloxacin d5
By using HPLC detection and palladium-based catalyst to accelerate the reaction during the preparation of the deuterated drug impurity norfloxacin-d5, combined with gradient elution, the problems of insufficient accuracy and low efficiency in traditional methods are solved, and the problem of High purity and high efficiency preparation effect.
Patent Information
- Application Number
- CN202410855964.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-28
- Publication Date
- 2024-11-12
AI Technical Summary
In the preparation method of the traditional deuterated drug impurity norfloxacin-d5, the accuracy is insufficient, the preparation efficiency is low and the purification effect is poor, which affects the product quality and output rate.
The completeness and purity of the reaction were detected by high performance liquid chromatography (HPLC), and the reaction was accelerated by accelerating the reaction with palladium-based catalyst and trimethyl borate, and the solubility difference was optimized by gradient elution.
Improve the accuracy and efficiency of the preparation process, ensuring high purity and high output rate of the product.
Smart Images

Figure CN118930481A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of deuterated drug impurity norfloxacin-d5, and specifically to a preparation method of deuterated drug impurity norfloxacin-d5. Background Art
[0002] Norfloxacin-d5 is a deuterated product of norfloxacin. Norfloxacin is a fluoroquinolone antibiotic that can inhibit the growth of Gram-positive and Gram-negative bacteria. Norfloxacin-d5 also has the antibacterial properties of norfloxacin, and as a deuterated product, it has unique value in the process of drug research and development, especially as a quantitative tracer. However, the traditional preparation method of deuterated drug impurity norfloxacin-d5 still has shortcomings. First, in the preparation process of traditional deuterated drug impurity norfloxacin-d5, TLC is generally used to detect the reaction degree and purity detection, which is not accurate enough and affects the quality of the product; second, in the preparation process of traditional deuterated drug impurity norfloxacin-d5, the preparation of intermediates and subsequent reactions are slow, which affects the preparation efficiency; third, column chromatography is used in traditional purification, but the elution effect is not good, which affects the yield. Therefore, it is necessary to design a preparation method for deuterated drug impurity norfloxacin-d5. Summary of the invention
[0003] The object of the present invention is to provide a method for preparing deuterated drug impurity norfloxacin-d5 to solve the problems raised in the above background technology.
[0004] To achieve the above object, the present invention provides the following technical solution: a method for preparing a deuterated drug impurity norfloxacin-d5, comprising the following steps: step one, preparing materials; step two, preparing an intermediate; step three, tritiated reaction; step four, removing impurities; step five, preparing a semi-finished product; step six, purification and testing;
[0005] In the above step 1, 50 to 60 parts of norfloxacin raw material, 10 to 15 parts of deuterated raw material and 5 to 8 parts of solvent are taken according to the number of components and set aside;
[0006] wherein in the above step 2, 3-chloro-4-fluoroaniline and diethyl ethoxymethylenemalonate (EMME) are subjected to a condensation reaction to form a primary intermediate, the primary intermediate is subjected to a cyclization reaction to obtain a cyclized lipid, the cyclized lipid is subjected to an ethylation reaction to obtain a secondary intermediate, the secondary intermediate is subjected to a hydrolysis reaction to obtain a hydrolyzate, and the hydrolyzate is subjected to a piperazine condensation reaction with anhydrous piperazine to obtain an intermediate of norfloxacin;
[0007] In the above step 3, the deuterated raw material and the norfloxacin intermediate are mixed in a solvent, a palladium-based catalyst is added, and the reaction progress is closely monitored during the process;
[0008] In the above step 4, the product obtained in step 3 is post-treated by distillation, extraction, washing, etc. to remove unreacted raw materials and by-products;
[0009] In the above step 5, the product obtained in step 4 is further subjected to a chemical reaction to obtain a crude product of norfloxacin-d5;
[0010] In the above step six, the crude product of norfloxacin-d5 is purified by purification techniques such as column chromatography and recrystallization to obtain a high-purity product, and the purity and structure of the purified product are tested by high performance liquid chromatography (HPLC) to ensure that it meets the standards.
[0011] As a further technical solution of the present invention, in the step 1, when preparing the materials, high performance liquid chromatography (HPLC) is used to detect the purity of the raw materials to ensure the high purity quality of the raw materials.
[0012] As a further technical solution of the present invention, in the step 2, it is necessary to heat to 120° C. under rapid stirring, and carry out the condensation reaction at 120-130° C. for 2 hours.
[0013] As a further technical solution of the present invention, in the step 2, trimethyl borate is added as a catalyst in the piperazine condensation reaction.
[0014] As a further technical solution of the present invention, in the step three, the reaction temperature is 70±5° C., and the reaction is carried out for 3 to 5 hours under stirring.
[0015] As a further technical solution of the present invention, in step three, high performance liquid chromatography (HPLC) is used to detect whether the reaction is complete.
[0016] As a further technical solution of the present invention, in step 4, the obtained reaction mixture is heated during the distillation process to vaporize the volatile components, and the liquid is collected through a condenser to obtain a relatively pure product.
[0017] As a further technical solution of the present invention, in step five, the reaction steps for obtaining the crude product of norfloxacin-d5 include cyclization, hydrolysis, etc.
[0018] As a further technical solution of the present invention, in step six, methanol and water are used as eluents to purify norfloxacin-d5, the ratio of methanol and water is adjusted to optimize the solubility difference, and gradient elution is used for elution.
[0019] As a further technical solution of the present invention, in step six, the target components are collected according to the separation of the components on the chromatographic column, and the collected components are concentrated, dried, etc. to obtain purified norfloxacin-d5.
[0020] Compared with the prior art, the invention has the following beneficial effects: the preparation method of the deuterated drug impurity norfloxacin-d5 uses high performance liquid chromatography (HPLC) to detect whether the reaction is complete in step three, and uses high performance liquid chromatography (HPLC) to detect the purity and structure of the purified product in step six to ensure that it meets the standard, thereby replacing the traditional TLC detection method, and can quickly separate components in a complex mixture, and accurately perform quantitative analysis through a detector, thereby improving accuracy; by adding trimethyl borate as a catalyst in the piperazine condensation reaction, and adding a palladium-based catalyst in the process of mixing the deuterated raw material and the norfloxacin intermediate, the piperazination yield and reaction rate are selectively improved, thereby improving the preparation efficiency; by using methanol and water as eluents to purify norfloxacin-d5 in step six, adjusting the ratio of methanol and water to optimize the solubility difference, and using a gradient elution method for elution, thereby improving the elution effect and output rate. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The figure is a flow chart of the method of the present invention. DETAILED DESCRIPTION
[0022] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0023] See also Figure 1 The present invention provides a technical solution: a method for preparing a deuterated drug impurity norfloxacin-d5, comprising the following steps: step one, preparing materials; step two, preparing an intermediate; step three, tritiated reaction; step four, removing impurities; step five, preparing a semi-finished product; step six, purification and testing;
[0024] Wherein in the above step 1, 50 to 60 parts of norfloxacin raw materials, 10 to 15 parts of deuterated raw materials and 5 to 8 parts of solvents are taken respectively according to the number of components, the norfloxacin raw materials are composed of 3-chloro-4-fluoroaniline, diethyl ethoxymethylene malonate (EMME) and anhydrous piperazine, and the ratio of 3-chloro-4-fluoroaniline, diethyl ethoxymethylene malonate (EMME) and anhydrous piperazine is 3:2:1, the deuterated raw materials are composed of deuterated ethylamine and deuterated toluene, and the composition ratio of deuterated ethylamine and deuterated toluene is 1:1, and the deuterated raw materials are composed of DMSO and water, and the composition ratio of DMSO and water is 2:3. When preparing the materials, high performance liquid chromatography (HPLC) is used to detect the purity of the raw materials to ensure the high purity quality of the raw materials;
[0025] wherein in the above step 2, the mixture is heated to 120° C. under rapid stirring, and 3-chloro-4-fluoroaniline and diethyl ethoxymethylenemalonate (EMME) are subjected to a condensation reaction at 120-130° C. for 2 hours to form a primary intermediate, the primary intermediate is subjected to a cyclization reaction to obtain a cyclized lipid, the cyclized lipid is subjected to an ethylation reaction to obtain a secondary intermediate, the secondary intermediate is subjected to a hydrolysis reaction to obtain a hydrolyzate, the hydrolyzate is subjected to a piperazine condensation reaction with anhydrous piperazine, and trimethyl borate is added as a catalyst in the piperazine condensation reaction to obtain an intermediate of norfloxacin;
[0026] In the above step 3, the deuterated raw material and the norfloxacin intermediate are mixed and stirred in a solvent at a reaction temperature of 70±5° C. for 3 to 5 hours, a palladium-based catalyst is added, and high performance liquid chromatography (HPLC) is used to detect whether the reaction is complete, and the reaction progress is closely monitored during the reaction;
[0027] In the above step 4, the product obtained in step 3 is post-treated by distillation, extraction, washing, etc. to remove unreacted raw materials and by-products, wherein the obtained reaction mixture is heated in the distillation process to vaporize the volatile components, and the liquid is collected by a condenser to obtain a relatively pure product;
[0028] In the above step 5, the product obtained in step 4 is subjected to further chemical reaction, including cyclization, hydrolysis, etc. to obtain a crude product of norfloxacin-d5;
[0029] In the above step six, the crude product of norfloxacin-d5 is purified by purification techniques such as column chromatography and recrystallization. Column chromatography is used to purify norfloxacin-d5 using methanol and water as eluents. The ratio of methanol and water is adjusted to optimize the solubility difference, and gradient elution is used for elution. The target components are collected according to the separation of each component on the chromatographic column. The collected components are concentrated, dried, etc. to obtain purified norfloxacin-d5. The purity and structure of the purified product are tested by high performance liquid chromatography (HPLC) to ensure that it meets the standards.
[0030] Based on the above, the advantages of the present invention are that, by using high performance liquid chromatography (HPLC) instead of the traditional TLC detection method, the present invention uses high performance liquid chromatography (HPLC) to detect whether the reaction is complete in step three, and performs purity and structure detection on the purified product by high performance liquid chromatography (HPLC) in step six to ensure that it meets the standards, and can quickly separate the components in a complex mixture, and perform accurate quantitative analysis by the detector, thereby improving accuracy; by adding trimethyl borate as a catalyst to the piperazine condensation reaction, and by adding a palladium-based catalyst during the mixing process of the deuterated raw material and the norfloxacin intermediate, the piperazination yield and reaction rate are selectively improved, and the preparation efficiency is improved; by using a gradient elution method for elution in step six, and using methanol and water as eluents to purify norfloxacin-d5, the ratio of methanol and water is adjusted to optimize the solubility difference, thereby improving the elution effect and yield.
[0031] It will be apparent to those skilled in the art that the invention is not limited to the details of the exemplary embodiments described above and that the invention can be implemented in other specific forms without departing from the spirit or essential features of the invention. Therefore, the embodiments should be considered exemplary and non-limiting in all respects, and the scope of the invention is defined by the appended claims rather than the foregoing description, and it is intended that all variations falling within the meaning and scope of the equivalent elements of the claims be included in the invention. Any reference numeral in a claim should not be considered as limiting the claim to which it relates.
Claims
1. A method for preparing deuterated drug impurity norfloxacin-d5, The following steps are involved: Step 1, preparing materials; Step 2, preparing intermediates; Step 3, tritiation reaction; Step 4, removing impurities; Step 5, preparing semi-finished products; Step 6, purification and testing; It is characterized by: In the above step 1, 50 to 60 parts of norfloxacin raw material, 10 to 15 parts of deuterated raw material and 5 to 8 parts of solvent are taken according to the number of components and set aside; wherein in the above step 2, 3-chloro-4-fluoroaniline and diethyl ethoxymethylenemalonate (EMME) are subjected to a condensation reaction to form a primary intermediate, the primary intermediate is subjected to a cyclization reaction to obtain a cyclized lipid, the cyclized lipid is subjected to an ethylation reaction to obtain a secondary intermediate, the secondary intermediate is subjected to a hydrolysis reaction to obtain a hydrolyzate, and the hydrolyzate is subjected to a piperazine condensation reaction with anhydrous piperazine to obtain an intermediate of norfloxacin; In the above step 3, the deuterated raw material and the norfloxacin intermediate are mixed in a solvent, a palladium-based catalyst is added, and the reaction progress is closely monitored during the process; In the above step 4, the product obtained in step 3 is post-treated by distillation, extraction, washing, etc. to remove unreacted raw materials and by-products; In the above step 5, the product obtained in step 4 is further subjected to a chemical reaction to obtain a crude product of norfloxacin-d5; In the above step six, the crude product of norfloxacin-d5 is purified by purification techniques such as column chromatography and recrystallization to obtain a high-purity product, and the purity and structure of the purified product are tested by high performance liquid chromatography (HPLC) to ensure that it meets the standards.
2. A method for preparing a deuterated drug impurity norfloxacin-d5 according to claim 1, Features: In the step 1, when preparing the raw materials, high performance liquid chromatography (HPLC) is used to detect the purity of the raw materials to ensure the high purity quality of the raw materials.
3. A method for preparing a deuterated drug impurity norfloxacin-d5 according to claim 1, Features: In the step 2, it is necessary to heat to 120° C. under rapid stirring, and carry out condensation reaction at 120-130° C. for 2 hours.
4. A method for preparing a deuterated drug impurity norfloxacin-d5 according to claim 1, Features: In the step 2, trimethyl borate is added as a catalyst in the piperazine condensation reaction.
5. A method for preparing a deuterated drug impurity norfloxacin-d5 according to claim 1, Features: In the step 3, the reaction temperature is 70±5° C., and the reaction is carried out for 3 to 5 hours under stirring.
6. A method for preparing a deuterated drug impurity norfloxacin-d5 according to claim 1, Features: In the step 3, high performance liquid chromatography (HPLC) is used to detect whether the reaction is complete.
7. A method for preparing a deuterated drug impurity norfloxacin-d5 according to claim 1, Features: In the step 4, the obtained reaction mixture is heated during the distillation process to vaporize the volatile components, and the liquid is collected through a condenser to obtain a relatively pure product.
8. A method for preparing a deuterated drug impurity norfloxacin-d5 according to claim 1, Features: In the step 5, the reaction steps for obtaining the crude product of norfloxacin-d5 include cyclization, hydrolysis, etc.
9. A method for preparing a deuterated drug impurity norfloxacin-d5 according to claim 1, Features: In step six, methanol and water are used as eluents to purify norfloxacin-d5, the ratio of methanol and water is adjusted to optimize the solubility difference, and gradient elution is used for elution.
10. A method for preparing a deuterated drug impurity norfloxacin-d5 according to claim 1, Features: In the step six, the target components are collected according to the separation of the components on the chromatographic column, and the collected components are concentrated, dried, etc. to obtain purified norfloxacin-d5.
